Biocon Ltd. — Capital/Financing Update 2025

Jun 20, 2025

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/46

June 20, 2025

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed the press release titled “ Biocon Limited Concludes a Rs 4,500 Crore (USD 523 million1) Equity Fundraise through a Qualified Institutions Placement (QIP) ”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Digitally signed by SIDDHART SIDDHARTH MITTAL H MITTAL Date: 2025.06.20 18:40:47 +05'30'

---

Siddharth Mittal Managing Director & CEO DIN: 03230757

Encl: Press Release

==> picture [78 x 34] intentionally omitted <==

PRESS RELEASE

Biocon Limited Concludes a Rs 4,500 Crore (USD 523 million[1] ) Equity Fundraise through a Qualified Institutions Placement (QIP)

BENGALURU, Karnataka, India , June 20, 2025

Biocon Limited (BSE code: 532523, NSE: BIOCON) , an innova�on-led global biopharmaceu�cal company, today announced the successful comple�on of a Qualified Ins�tu�ons Placement (QIP), raising Rs 4,500 crore through the issuance of 13,63,63,635 equity shares of face value ₹5 each to eligible qualified ins�tu�onal buyers at the issue price of Rs 330 per Equity Share (including a premium of Rs. 325 per Equity Share).

The QIP, which opened on June 16, 2025, and closed on June 19, 2025, witnessed robust investor interest from a diverse group of domes�c and interna�onal investors, underscoring strong confidence in Biocon’s growth prospects.

Siddharth Mi�al, CEO and Managing Director, Biocon Limited, said , "The strong response to our QIP reflects deep investor convic�on in Biocon’s differen�ated strategy and consistent execu�on. This capital raise further strengthens our balance sheet, enabling us to invest in innova�on, expand global access to lifesaving biopharmaceu�cals, and advance our purpose of delivering affordable healthcare solu�ons that address pressing health inequi�es worldwide.”

Key Transac�on Highlights:

• First equity fundraise done by Biocon since its IPO in 2004.

• Biocon’s differen�ated business model and growth poten�al.

• funds, insurance companies and foreign ins�tu�onal investors. Some of the leading names who par�cipated in the issue included SBI Mutual Fund, ICICI Pruden�al Mutual Fund, HDFC Life Insurance, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI General Insurance, Government Pension Fund Global and Blackrock.

• The proceeds from the QIP will be u�lized for:

• Purchase of outstanding op�onally conver�ble debentures issued by our Subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alterna�ve Investment Trust AIF Scheme – 2

• instruments issued and/or borrowings availed by our Company, and/or mee�ng other financial commitments of our Company; and

• General corporate purposes

1 1 USD – Rs 86

1

==> picture [78 x 34] intentionally omitted <==

The Company received shareholder approval for the fundraise via a postal ballot on June 4, 2025. The post-issue shareholding of the Promoter[2] and Promoter Group[3] stands at 54.45%.

Legal Counsels : Kotak Mahindra Capital Company Limited, BofA India Securi�es India Limited and Goldman Sachs (India) Securi�es Private Limited acted as Book Running Lead Managers to the QIP. JSA Advocates & Solicitors was the Legal Counsel to the Company while Cyril Amarchand Mangaldas and Linklaters Singapore Pte. Ltd. were the Legal Counsels to the Book Running Lead Managers.

About Biocon Limited :

Biocon Limited , publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innova�onled global biopharmaceu�cals company commi�ed to enhance affordable access to complex therapies for chronic condi�ons like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formula�ons in the US, Europe & key emerging markets. Website: www.biocon.com; Follow-us on Twi�er: @bioconlimited for company updates

==> picture [468 x 178] intentionally omitted <==

----- Start of picture text -----

For More Informa�on:
MEDIA INVESTORS
Biocon Group Biocon
Seema Ahuja Saurabh Paliwal
Global Head of Communica�ons & Head - Investor Rela�ons
Corporate Brand +91 95383 80801
+91 99723 17792 saurabh.paliwal@biocon.com
seema.ahuja@biocon.com
Biocon
Calvin Printer
Head - Corporate Communica�ons
+91 70329 69537
calvin.printer@biocon.com
----- End of picture text -----

Disclaimer:

The securi�es described in this announcement have not been and will not be registered under the U.S. Securi�es Act of 1933, as amended (the “U.S. Securi�es Act”) and may not be offered or sold within the United States, except pursuant to an exemp�on from, or in a transac�on not subject to, the registra�on requirements of the U.S. Securi�es Act and applicable state securi�es laws. No public offering of securi�es in the United States is contemplated.

Forward-Looking Statements: Biocon

This press release may include statements of future expecta�ons and other forward-looking statements based on management's current expecta�ons and beliefs concerning future developments and their poten�al effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertain�es that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expecta�ons include, amongst other: general economic and business condi�ons in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and interna�onal interest rates, change in laws and regula�ons that apply to the Indian and global biotechnology and pharmaceu�cals industries, increasing compe��on in and the condi�ons of the Indian and global biotechnology and pharmaceu�cals industries, changes in poli�cal condi�ons in India and changes in the foreign exchange control regula�ons in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obliga�on to update any par�cular forward-looking statement contained in this release.

2 Kiran Mazumdar-Shaw and Glentec Interna�onal

3 The individuals and en��es cons�tu�ng the promoter group of our Company as determined in accordance with Regula�on 2(1)(pp) of the SEBI ICDR Regula�ons

2